Omeros Corporation's shares fell over 19% following the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a negative opinion on the company's marketing authorization application for narsoplimab, a treatment for TA-TMA. The Schall Law Firm has launched an investigation into whether Omeros made false or misleading statements or failed to disclose important information to investors. This legal action targets shareholders who suffered losses due to the stock drop. Investors are encouraged to contact the law firm to discuss their rights and potential claims.
The global golf simulators market, valued at $2.4 billion in 2025, is projected to grow to $5.5 billion by 2035 at an 8.6% CAGR. Growth is fueled by technological improvements, increased commercial and residential use, and rising demand for indoor go...
Aimei Health Technology Co., Ltd. has terminated its business combination agreement with United Hydrogen Group Inc. due to failure to complete the merger by the agreed deadline. The termination was effective immediately as the closing did not occur b...
BellRing Brands has appointed Michael Axelrod as its new President and CEO, effective July 29, 2026, succeeding Darcy Davenport who will retire but remain as an advisor. Axelrod brings over 30 years of experience in consumer packaged goods, including...
Capital Power Corporation has entered a long-term energy supply agreement to provide 250 megawatts of power to Meta's new data centre in Sturgeon County, Alberta, expected to be operational in late 2028. This deal strengthens Capital Power's position...
A securities class action lawsuit has been filed against Megan Holdings Limited by investors who purchased shares during its September 2025 IPO or between September 2025 and May 2026. The lawsuit alleges the company made false and misleading statemen...
